Therapeutic Recommendations for Nephroblastoma

  • STATUS
    Recruiting
  • End date
    Sep 30, 2026
  • participants needed
    1000
  • sponsor
    French Africa Pediatric Oncology Group
Updated on 19 February 2024
wilms' tumour / nephroblastoma

Summary

The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.

Description

The study is based on results form 2 previous studies carried out by the GFAOP. This study aims to evaluate the capacity of units to follow the recommendations in the protocol. It will look mainly at treatment compliance and outcome for the children treated. The study will also evaluate the improvement in treatment compliance and reporting. This work will help the group to evaluate future needs in participating units and help us adapt treatment programmes to local conditions.

Details
Condition Malignant neoplasm of kidney, kidney cancer, Hereditary Neoplastic Syndrome, hereditary cancer syndromes, Nephroblastoma, kidney cancer, hereditary cancer syndromes
Age 1-18 years
Treatment data collection
Clinical Study IdentifierNCT04423484
SponsorFrench Africa Pediatric Oncology Group
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Unilateral Nephroblastoma Tumor Not previously treated The general health of
the child will permit treatment

Exclusion Criteria

Bilateral Nephroblastoma tumor Previously treated Disease too advanced Doubt
concerning the diagnosis Treatment Refusal
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.